Preferred Label : Zilurgisertib;
NCIt synonyms : ALK2 Inhibitor INCB000928;
NCIt definition : An inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2;
ACVR1; ACTR-I), with potential anti-anemic and ossification suppressive activities.
Upon administration, zilurgisertib targets, binds to and inhibits the activity of
ALK-2. This prevents ALK2-mediated signaling and ALK2-mediated excessive bone morphogenetic
protein (BMP) signaling. This may suppress heterotopic ossification (HO). As ALK-2
enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of
iron homeostasis, zilurgisertib is able to decrease hepcidin expression in the liver,
thereby increasing and restoring plasma iron levels, enhancing erythropoiesis, and
correcting anemia of chronic disease (ACD). ALK2, a serine/threonine receptor kinase
and type I cell surface receptor for BMPs, is constitutively activated due to activating
mutations in inflammatory conditions, various types of cancer, and in fibrodysplasia
ossificans progressiva (FOP). Elevated serum hepcidin levels enhance storage of iron,
reduce iron availability and causes iron deficiency anemia.;
UNII : L5Z9S25HO2;
CAS number : 2173389-57-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2173389-57-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : INCB-000928; INCB 000928; (INCB-00928; (INCB 00928;
NCI Metathesaurus CUI : CL1413026;
Origin ID : C175551;
UMLS CUI : C5783396;
Semantic type(s)
- concept_is_in_subset
- has_target
